Daver N et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and Magrolimab (Magro) in patients (Pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2022;Abstract 61.

DiNardo CD et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. EHA 2022;Abstract P510.

Döhner H et al. Towards precision medicine for AML. Nat Rev Clin Oncol 2021;18(9):577-90. Abstract

Erba H et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. EHA 2022;Abstract S100.

Erba HP et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. ASH 2022;Abstract 64.

Garciaz S et al. Long-term survival of acute myeloid leukemia responding patients who stopped azacytidine and/or venetoclax because of poor tolerance or physician choice: A retrospective multicenter study from the french innovative leukemia organization (FILO). ASH 2022;Abstract 2737.

Issa GC et al. The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (pts) with KMT2A-rearranged or NPM1 mutant AML: Updated results of a phase (Ph) 1 study. ASH 2022;Abstract 63.

Lachowiez CA et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: A post-hoc, propensity score-matched, cohort study. Lancet Hemaetol 2022;9(5):e350-60. Abstract

Pratz K et al. Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. ASH 2022;Abstract 219.

Pratz KW et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022;40(8):855-65. Abstract

Röllig C et al. Single versus double induction with “7 + 3” containing 60 versus 90 mg daunorubicin for newly diagnosed AML: Results from the randomized controlled SAL dauno-double trial. ASH 2022;Abstract 217.

Russell NH et al. FLAG-IDA combined with gemtuzumab ozogamicin (GO) improves event free survival in younger patients with newly diagnosed acute myeloid leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. ASH 2022;Abstract 218.

Short N et al. Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. ASH 2022;Abstract 831.

Zhu R et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. Signal Trasduct Target Ther 2021;6(1):186. Abstract